Entering text into the input field will update the search result below

Genmab down 2% as it drops enapotamab vedotin, development for treatment of solid cancer

Nov. 24, 2020 1:16 PM ETGenmab A/S (GMAB) StockGMABBy: Meghavi Singh, SA News Editor
  • Genmab (GMAB -2.1%) after news that it's discontinuing its Phase 1/2 study of enapotamab vedotin and dropping development as the data from the expansion cohorts did not meet Genmab’s stringent criteria for proof-of-concept.
  • Enapotamab vedotin is fully owned by Genmab and the drug

Recommended For You

More Trending News

About GMAB Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
GMAB--
Genmab A/S